Center for Population Health IT, Department of Health Policy and Management, Johns Hopkins Bloomberg School of Public Health, Hampton House HH502, 624 N. Broadway, Baltimore, MD, 21205, USA.
, Cortica US, 425 Broadway, New York, NY, 10013, USA.
Arthritis Res Ther. 2018 May 2;20(1):79. doi: 10.1186/s13075-018-1580-5.
This study estimated the extent and predictors of primary nonadherence (i.e., prescriptions made by physicians but not initiated by patients) to methotrexate and to biologics or tofacitinib in rheumatoid arthritis (RA) patients who were newly prescribed these medications.
Using administrative claims linked with electronic health records (EHRs) from multiple healthcare provider organizations in the USA, RA patients who received a new prescription for methotrexate or biologics/tofacitinib were identified from EHRs. Claims data were used to ascertain filling or administration status. A logistic regression model for predicting primary nonadherence was developed and tested in training and test samples. Predictors were selected based on clinical judgment and LASSO logistic regression.
A total of 36.8% of patients newly prescribed methotrexate failed to initiate methotrexate within 2 months; 40.6% of patients newly prescribed biologics/tofacitinib failed to initiate within 3 months. Factors associated with methotrexate primary nonadherence included age, race, region, body mass index, count of active drug ingredients, and certain previously diagnosed and treated conditions at baseline. Factors associated with biologics/tofacitinib primary nonadherence included age, insurance, and certain previously treated conditions at baseline. The area under the receiver operating characteristic curve of the logistic regression model estimated in the training sample and applied to the independent test sample was 0.86 and 0.78 for predicting primary nonadherence to methotrexate and to biologics/tofacitinib, respectively.
This study confirmed that failure to initiate new prescriptions for methotrexate and biologics/tofacitinib was common in RA patients. It is feasible to predict patients at high risk of primary nonadherence to methotrexate and to biologics/tofacitinib and to target such patients for early interventions to promote adherence.
本研究旨在评估类风湿关节炎(RA)患者新处方甲氨蝶呤和生物制剂/托法替尼时,首次未用药(即医生开具但患者未开始使用的处方)的程度和预测因素。
使用来自美国多个医疗服务提供者组织的行政索赔数据与电子健康记录(EHR)进行链接,从 EHR 中确定新处方甲氨蝶呤或生物制剂/托法替尼的 RA 患者。索赔数据用于确定用药或治疗的情况。在训练和测试样本中建立并测试了预测首次未用药的逻辑回归模型。根据临床判断和 LASSO 逻辑回归选择预测因素。
新处方甲氨蝶呤的患者中,有 36.8%在 2 个月内未开始使用甲氨蝶呤;新处方生物制剂/托法替尼的患者中,有 40.6%在 3 个月内未开始使用。与甲氨蝶呤首次未用药相关的因素包括年龄、种族、地区、体重指数、活性药物成分的数量以及基线时某些已诊断和治疗的疾病。与生物制剂/托法替尼首次未用药相关的因素包括年龄、保险以及基线时某些已治疗的疾病。在训练样本中估计并应用于独立测试样本的逻辑回归模型的接收者操作特征曲线下面积,分别为 0.86 和 0.78,用于预测对甲氨蝶呤和生物制剂/托法替尼的首次未用药。
本研究证实,RA 患者新处方甲氨蝶呤和生物制剂/托法替尼未使用的情况较为常见。预测对甲氨蝶呤和生物制剂/托法替尼首次未用药高风险的患者,并针对此类患者进行早期干预以促进用药依从性是可行的。